Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing therapies for blood coagulation disorders. Its lead product, HMB-001, is a bispecific antibody in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and in Phase 2 for Factor VII deficiency. The second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 for subcutaneous prophylactic treatment of Von Willebrand disease. The company also has multiple preclinical and discovery-stage assets. Hemab aims to reimagine the treatment of bleeding disorders to sustain life and human resilience.

Hemab Therapeutics is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol COAG. The company's financials are reported in US Dollars (USD), as it is based in the United States. The exchange and currency reflect its primary listing in the US equity markets, making it accessible to investors trading on Nasdaq.

Hemab Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biotech company, it focuses on developing innovative therapies for blood coagulation disorders. Biotechnology companies like Hemab engage in research and development of drugs, often with a high-risk, high-reward profile, targeting unmet medical needs in areas such as rare bleeding disorders.

Hemab Therapeutics is headquartered in Cambridge, Massachusetts, United States. The company operates in the United States and Denmark, as indicated in its description. It serves patients with blood coagulation disorders, including Glanzmann thrombasthenia, Factor VII deficiency, and Von Willebrand disease. Its therapies are being developed for prophylactic treatment, aiming to address unmet needs in both US and international markets.

Hemab Therapeutics has two clinical-stage products. HMB-001 is a bispecific antibody in Phase 1/2 for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency, both for prophylactic use. HMB-002 is a monovalent antibody in Phase 1/2 for subcutaneous prophylactic treatment of Von Willebrand disease. Additionally, the company is advancing multiple preclinical and discovery-stage assets. These products target rare bleeding disorders, aiming to provide new treatment options for patients with limited existing therapies.